These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 26713633)

  • 21. Recent developments and future challenges in immune checkpoint inhibitory cancer treatment.
    Koster BD; de Gruijl TD; van den Eertwegh AJ
    Curr Opin Oncol; 2015 Nov; 27(6):482-8. PubMed ID: 26352539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists.
    Kakavand H; Wilmott JS; Long GV; Scolyer RA
    Pathology; 2016 Feb; 48(2):194-202. PubMed ID: 27020392
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape.
    Emens LA; Ascierto PA; Darcy PK; Demaria S; Eggermont AMM; Redmond WL; Seliger B; Marincola FM
    Eur J Cancer; 2017 Aug; 81():116-129. PubMed ID: 28623775
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radiotherapy and immunotherapy: Can this combination change the prognosis of patients with melanoma brain metastases?
    Franceschini D; Franzese C; Navarria P; Ascolese AM; De Rose F; Del Vecchio M; Santoro A; Scorsetti M
    Cancer Treat Rev; 2016 Nov; 50():1-8. PubMed ID: 27566962
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Harnessing the immune system for the treatment of melanoma: current status and future prospects.
    Guennoun A; Sidahmed H; Maccalli C; Seliger B; Marincola FM; Bedognetti D
    Expert Rev Clin Immunol; 2016 Aug; 12(8):879-93. PubMed ID: 27070898
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic Advances and Treatment Options in Metastatic Melanoma.
    Johnson DB; Sosman JA
    JAMA Oncol; 2015 Jun; 1(3):380-6. PubMed ID: 26181188
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.
    Faghfuri E; Faramarzi MA; Nikfar S; Abdollahi M
    Expert Rev Anticancer Ther; 2015; 15(9):981-93. PubMed ID: 26313415
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Immunotherapies - Overview, mode of action and clinical implications].
    Bill R; Schardt J
    Ther Umsch; 2019 Sep; 76(4):187-194. PubMed ID: 31498037
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of systemic therapies in the management of melanoma brain metastases.
    Lyle M; Long GV
    Curr Opin Oncol; 2014 Mar; 26(2):222-9. PubMed ID: 24434634
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma.
    McDermott D; Lebbé C; Hodi FS; Maio M; Weber JS; Wolchok JD; Thompson JA; Balch CM
    Cancer Treat Rev; 2014 Oct; 40(9):1056-64. PubMed ID: 25060490
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.
    Weber J
    Semin Oncol; 2010 Oct; 37(5):430-9. PubMed ID: 21074057
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies.
    Robert C; Soria JC; Eggermont AM
    Eur J Cancer; 2013 Sep; 49(14):2968-71. PubMed ID: 23907003
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cancer immunology - development of novel anti-cancer therapies.
    Rothschild SI; Thommen DS; Moersig W; Müller P; Zippelius A
    Swiss Med Wkly; 2015; 145():w14066. PubMed ID: 25668078
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted agents and immunotherapies: optimizing outcomes in melanoma.
    Luke JJ; Flaherty KT; Ribas A; Long GV
    Nat Rev Clin Oncol; 2017 Aug; 14(8):463-482. PubMed ID: 28374786
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy Combinations With Checkpoint Inhibitors in Metastatic Melanoma: Current Approaches and Future Directions.
    Atkins M
    Semin Oncol; 2015 Dec; 42 Suppl 3():S12-9. PubMed ID: 26598055
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Contact immunotherapy enhances the therapeutic effects of nivolumab in treating in-transit melanoma: Two cases reports.
    Fujimura T; Furudate S; Kakizaki A; Kambayashi Y; Haga T; Hashimoto A; Aiba S
    J Dermatol; 2016 Jun; 43(6):686-9. PubMed ID: 26663262
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies.
    Eggermont AM; Maio M; Robert C
    Semin Oncol; 2015 Jun; 42(3):429-35. PubMed ID: 25965361
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer.
    Anagnostou VK; Brahmer JR
    Clin Cancer Res; 2015 Mar; 21(5):976-84. PubMed ID: 25733707
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Melanoma and immunotherapy.
    Eggermont AM; Schadendorf D
    Hematol Oncol Clin North Am; 2009 Jun; 23(3):547-64, ix-x. PubMed ID: 19464602
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Update on immunotherapy in melanoma.
    Green J; Ariyan C
    Surg Oncol Clin N Am; 2015 Apr; 24(2):337-46. PubMed ID: 25769716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.